Table 1 Clinical features of enrolled samples.

From: Identification of a methylomics-associated nomogram for predicting overall survival of stage I–II lung adenocarcinoma

Characteristics

Total (n = 393)

Training dataset (n = 276)

Testing dataset (n = 117)

Sex

Female

212 (53.94)

144 (52.17)

68 (58.12)

Male

181 (46.06)

132 (47.83)

49 (41.88)

Age

≤ 65

195 (49.62%)

140 (50.72%)

55 (47.01%)

> 65

189 (48.09%)

130 (47.1%)

59 (50.43%)

Not available

9 (2.29%)

6 (2.17%)

3 (2.56%)

Stage

Stage I

275 (69.97%)

192 (69.57%)

83 (70.94%)

Stage II

118 (30.03%)

84 (30.43%)

34 (29.06%)

M

M0

263 (66.92%)

194 (70.29%)

69 (58.97%)

MX

125 (31.81%)

78 (28.26%)

47 (40.17%)

Not available

5 (1.27%)

4 (1.45%)

1 (0.85%)

T

T1

154 (39.19%)

107 (38.77%)

47 (40.17%)

T2

209 (53.18%)

151 (54.71%)

58(49.57%)

T3

30 (7.63%)

18 (6.52%)

12 (10.26%)

N

N0

306 (77.86%)

208 (75.36%)

98 (83.76%)

N1

75 (19.08%)

58 (21.01%)

17 (14.53%)

NX

12 (3.05%)

10 (3.62%)

2 (1.71%)

Location

Central lung

45 (11.45%)

33 (11.96%)

12 (10.26%)

Peripheral lung

84 (21.37%)

63 (22.83%)

21 (17.95%)

Not available

202 (51.4%)

134 (48.55%)

68 (58.12%)

Unknown

62 (15.78%)

46 (16.67%)

16 (13.68%)

Neoadjuvant treatment

No

391 (99.49%)

274 (99.28%)

117 (100%)

Yes

2 (0.51%)

2 (0.72%)

 

Site

L-Lower

64 (16.28%)

47 (17.03%)

17 (14.53%)

L-Upper

87 (22.14%)

59 (21.38%)

28 (23.93%)

R-Lower

61 (15.52%)

44 (15.94%)

17 (14.53%)

R-Middle

13 (3.31%)

8 (2.9%)

5 (4.27%)

R-Upper

160 (40.71%)

114 (41.3%)

46 (39.32%)

Not available

8 (2.04%)

4 (1.45%)

4 (3.42%)

Residual tumor

R0

252 (64.12%)

175 (63.41%)

77 (65.81%)

R1

4 (1.02%)

3 (1.09%)

1 (0.85%)

Not available

137 (34.86%)

98 (35.51%)

39 (33.33%)

Race

Asian

4 (1.02%)

3 (1.09%

1 (0.85%)

Black or African American

44 (11.2%)

31 (11.23%)

13 (11.11%)

White

315 (80.15%)

221 (80.07%)

94 (80.34%)

Not available

30 (7.63%)

19 (6.88%)

11 (9.40%)

Back to article page